A

Amylyx Pharmaceuticals

Biopharmaceutical company developing neurodegenerative therapies

Director, Clinical Sciences

Clinical Research OperationsConfirmed live in the last 24 hours
Full-timeRemote in USA

About the Job

Requirements

  • A Master's degree in a relevant scientific or healthcare discipline and at least 8 years of relevant drug development experience are required; an equivalent combination of advanced education and relevant industry experience may be considered.
  • Knowledge of Phase 1–3 drug development.
  • Knowledge of clinical trial implementation and sponsor/site interactions for clinical trials.
  • Prior experience working within endocrine, neurology, or rare disease indications.
  • Knowledge of relevant applications of Good Clinical Practice, ICH, FDA, EMEA, and other relevant guidelines and regulations.
  • Strong collaborative teamwork skills.
  • Attention to detail and communication skills.

Responsibilities

  • Collaborate with the clinical development team in reviewing, analyzing, and interpreting study results.
  • Provide scientific support on ongoing Phase I to III clinical trials and contribute to planning and designing upcoming clinical studies.
  • Monitor and review study data, including labs, safety data, and patient eligibility.
  • Author and/or review clinical trial-related documents, including protocols, CRFs, informed consent, protocol deviations, monitoring plans, and regulatory documents.
  • Contribute to regulatory documents, including CSRs, Investigator’s Brochures, and clinical sections of INDs and CTAs.
  • Interact with external medical/scientific advisors, thought leaders, and clinical investigators in the therapeutic areas, as well as internal management and drug development staff, to prepare, revise, maintain, and efficiently execute the clinical development plan.

Desired Qualifications

  • An advanced degree (M.D., Ph.D., or Pharm.D.) is preferred.

About the Company

Amylyx Pharmaceuticals

Biopharmaceutical company developing neurodegenerative therapies

Amylyx Pharmaceuticals develops treatments for neurodegenerative diseases, with a focus on ALS and Alzheimer's disease. Its main asset is AMX0035, currently in clinical trials, including the CENTAUR study for ALS and the PEGASUS study for late mild cognitive impairment or early dementia due to Alzheimer’s disease. The company advances products through rigorous, randomized, double-blind, placebo-controlled trials to demonstrate safety and efficacy before pursuing commercialization. In addition to research, Amylyx engages in awareness and community campaigns to support patients, caregivers, and researchers. The company aims to bring validated therapies to market to improve patient outcomes and generate revenue by selling treatments to healthcare providers and patients.

Company size
51-200
Company stage
IPO
Headquarters
Cambridge, MA
Founded
2013

Recently Posted Jobs

Explore more opportunities at Amylyx Pharmaceuticals

See more jobs